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IL-7R  (IL7R) is required for normal lym-
phoid development (Peschon et al., 1994). Loss-
of-function  mutations  in  this  receptor  cause 
severe combined immune deficiency (OMIM 
608971; Puel et al., 1998). IL-7R heterodi-
merizes either with IL-2R  (IL2RG) to form 
a receptor to IL-7 or with cytokine receptor-
like factor 2 (CRLF2) in the receptor for thy-
mic stromal lymphopoietin (TSLP; Noguchi 
et al., 1993; Liu et al., 2007). TSLP is a cyto-
kine that mediates inflammation and allergy ex-
pressed on macrophages and T cells (Liu et al., 
2007). Signaling from the TSLP receptor acti-
vates signal transducer and activator of tran-
scription (STAT5) by phosphorylation of JAK1 
and JAK2 through association with IL-7R and 
CRLF2, respectively (Rochman et al., 2010).
We and others have recently described the 
aberrant expression of CRLF2 in B cell precursor 
acute lymphoblastic leukemia (BCP-ALL) caused 
by genomic aberrations (Mullighan et al., 2009; 
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Interleukin-7 receptor  (IL7R) is required for normal lymphoid development. Loss-of-
function mutations in this gene cause autosomal recessive severe combined immune deficiency. 
Here, we describe somatic gain-of-function mutations in IL7R in pediatric B and T acute 
lymphoblastic leukemias. The mutations cause either a serine-to-cysteine substitution at 
amino acid 185 in the extracellular domain (4 patients) or in-frame insertions and deletions 
in the transmembrane domain (35 patients). In B cell precursor leukemias, the mutations 
were associated with the aberrant expression of cytokine receptor-like factor 2 (CRLF2), 
and the mutant IL-7R proteins formed a functional receptor with CRLF2 for thymic stromal 
lymphopoietin (TSLP). Biochemical and functional assays reveal that these IL7R mutations 
are activating mutations conferring cytokine-independent growth of progenitor lymphoid 
cells. A cysteine, included in all but three of the mutated IL-7R alleles, is essential for the 
constitutive activation of the receptor. This is the first demonstration of gain-of-function 
mutations of IL7R. Our current and recent observations of mutations in IL7R and CRLF2, 
respectively suggest that the addition of cysteine to the juxtamembranous domains is a 
general mechanism for mutational activation of type I cytokine receptors in leukemia.
© 2011 Shochat et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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All mutations were heterozygous and somatic, as they 
were absent in remission bone marrows. The mutated mRNA 
was expressed (Fig. 1 D and Fig. S1). JAK2 mutations were 
present in three samples, whereas no mutations in JAK1 were 
identified. Four patients relapsed. Examination of DNA de-
rived from matched diagnostic and relapse samples revealed 
clonal diversification. The same IL7R mutation was present 
in both diagnosis and relapse in patient M61.  IL7R mutation 
was present only at relapse in patient M122, whereas CRLF2 
expression was already noted at diagnosis, suggesting that  IL7R 
mutation was a progression event. Conversely, in two pa-
tients, M90 and M112 CRLF2 abnormalities and  IL7R 
mutations were present at diagnosis and not in relapse, sug-
gesting that relapse arose from a different subclone. These 
findings are consistent with the recent studies on the marked 
clonal diversity of B- and T-ALLs (Rothman et al., 2005; 
Anderson et al., 2011; Clappier et al., 2011).
We next tested whether the somatic mutations in IL-7R   
are gain-of-function mutations that cooperate with CRLF2 
to form a constitutively active TSLP receptor. We used the 
IL-3–dependent mouse pro–B cells BaF3 (not expressing en-
dogenous TSLP receptor; Fig. S2) to generate cell lines that 
express either WT or mutated IL7R alone or together with 
CRLF2. We expressed IL-7R S185C and the c.819 Ins12 
(CCCCCGTGCCTA) 243 insertion (Ins) PPCL (herein 
“InsPPCL”) representing the two types of mutations. All pro-
teins were expressed at the cell membrane as demonstrated by 
flow cytometry (Fig. 2 A). 1 wk after IL-3 withdrawal, only 
cells transduced with CRLF2 and mutated IL-7R survived 
(Fig. 2, B and C). Closer examination revealed two popula-
tions of surviving BaF3 cells transduced with CRLF2 and 
IL-7R InsPPLC, suggesting that IL-7R InsPPLC provided 
survival advantage by itself. Indeed, growth assays of BaF3 
cells transduced with the IL-7R InsPPLC construct in the 
absence of CRLF2 (Fig. 2 B) revealed robust cytokine- 
independent growth. In contrast, BaF3 cells expressing IL-7R 
S185C required CRLF2 co-expression for survival. Cells ex-
pressing only CRLF2, IL-7R S185C, or WT CRLF2 and 
WT IL-7R did not grow in the absence of cytokines.
Russell et al., 2009; Hertzberg et al., 2010; Yoda et al., 2010). 
These are either translocations into the immunoglobulin heavy 
locus or interstitial deletions creating chimeric P2RY8-CRLF2 
transcripts. Additional mutations in the pathway, most com-
monly in JAK2 but occasionally in JAK1 or in CRLF2 itself, 
occur in approximately half of the patients. Overall, CRLF2 
deregulation occurs in 5–10% of childhood ALL and in 60% 
of children with Down syndrome and BCP-ALL (DS-ALL; 
Izraeli, 2010) and is associated with a worse prognosis (Cario 
et al., 2010; Harvey et al., 2010; Yoda et al., 2010; Ensor et al., 
2011). Importantly, these leukemias may be sensitive to JAK 
inhibitors, suggesting the potential for a targeted therapy.
IL7R is constitutively expressed in BCP-ALL, and the 
formation of a TSLP receptor is plausible in cases with ab-
errant expression of CRLF2 (Hertzberg et al., 2010). Re-
ceptor association is functional because primary BCP-ALL 
cells expressing CRLF2 respond to TSLP, but not to IL-7, 
by phosphorylation of STAT5 and RPS6 (Tasian et al., 
2010). We therefore hypothesized that IL7R might be muta-
tionally activated in ALL samples expressing CRLF2. In ad-
dition to confirmation of this hypothesis, we also report the 
identification of such mutations in 10% of T-ALLs, thereby 
demonstrating a general involvement of the IL-7R in ALL.
RESULTS AND DISCUSSION
We screened DNA derived from 133 bone marrow samples of 
BCP-ALLs, including 62 DS-ALLs, with aberrant expression 
of CRLF2 and additional 153 BCP-ALL not expressing CRLF2 
including 21 DS-ALLs. Nine leukemias with IL7R mutations 
were identified. The rate of mutations in the CRLF2 group 
(8/133; 6%) was significantly higher than the rest of BCP-
ALLs (1/153; 0.6%; P = 0.01, Fisher’s exact test; Table I).
Two types of mutations in IL7R were identified (Fig. 1, 
A and B, and Table I). Replacement of serine with cysteine 
at position 185 at the extracellular domain in four patients 
and complex in-frame insertions and deletions resulted in the 
addition of 3–7 aa at the transmembrane domain in 5 patients. 
Whereas the inserted amino acids varied from patient to 
patient, cysteine was always included (Fig. 1 C).
Table I.  Patients with B cell precursor ALL and somatic mutations in IL7R
ID IL7R mutation DNA IL-7R mutation protein CRLF2 JAK2 Gender Age at Dx  WBC/liter Events
yr
DS46 c.819 Ins 12 243 InsPPCL P2RY8-CRLF2 mut M 4.9 30.5 3 109 first CCR
DS92 c.642 A>T S185C IGH translocation WT M 15.1 112.8 3 109 first CCR
M90 c.828 Ins7 Del T 246 InsKCH P2RY8-CRLF2 WT M 1.7 123 3 109 relapse
M112 c.642 A>T S185C P2RY8-CRLF2 mut F 14.3 9.7 3 109 relapse
M117 c.814 Ins13 Del A 241 InsFSCGP P2RY8-CRLF2 mut F 10.3 7 3 109 first CCR
M122 c.642 A>T S185C P2RY8-CRLF2 WT M 7.0 7.3 3 109 relapse
M124 c.820 Ins10 Del C 244 InsCHL High expression WT M 4.9 8.9 3 109 first CCR
M223 c.642 A>T S185C P2RY8-CRLF2 WT M 8.0 27 3 109 first CCR
M61 c.820 ins21 244 InsPPVCSVT CRLF2 not expressed WT M 10.7 152 3 109 relapse
DS, Down syndrome; M, male; F, female; mut, mutated at JAK2 R683; CCR, continuous complete remission; Dx, Diagnosis; Del, Deletion; Ins, Insertion; WBC, white blood  
cells count.JEM VOL. 208, May 9, 2011  903
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Biochemical analysis of proteins extracted from BaF3 
cell was consistent with the growth assays (Fig. 2 C). Both 
Stat5 and RPS6 were phosphorylated in the absence of 
cytokine in BaF3 cells transduced with the IL-7R InsPPCL 
alone, but not in cells expressing IL-7R S185C or WT IL-7R. 
Co-expression of CRLF2 with each of these mutated IL-7R 
proteins, but not with the WT IL-7R caused constitutive 
phosphorylation of Stat5 and RPS6. Together, the func-
tional and biochemical assays demonstrate that the two 
types of somatic mutations in IL7R are activating muta-
tions causing cytokine independent growth of mouse pro–
B cells and constitutive activation of STAT and mTOR 
pathways. In accordance with the functional studies, the 
single patient in whom IL7R was mutated in the absence 
of CRLF2 expression (Table I, patient M61) had the inser-
tion type of mutation with the CRLF2-independent acti-
vation phenotype.
To see if CRLF2 and mutated IL-7R form a functional 
TSLP receptor, BaF3 cells expressing CRLF2 and either WT 
or mutated IL-7R were starved from IL-3 and treated with 
100 ng/ml TSLP for 25 min. As noted in Fig. 2 C, cells ex-
pressing  the  mutated  receptor  exhibited  Stat5  and  RPS6 
phosphorylation in the absence of cytokine. Yet all cells re-
sponded to TSLP with a marked increase in Stat5 and RPS6 
phosphorylation (Fig. 3 A). Thus, CRLF2 and mutated IL-7R 
form a functional TSLP receptor. To test if the presence of 
mutated IL-7R sensitizes BaF3 cells to TSLP, we treated 
BaF3 transduced with CRLF2 and either WT IL-7R or IL-7R 
S185C with increasing doses of TSLP in the absence of IL-3 
(Fig. 3 B). Cells expressing CRLF2–IL-7R S185C grew in 
the absence of cytokines, but also demonstrated higher sensi-
tivity to TSLP. As little as 0.1 ng/ml TSLP doubled the 
growth rate, but had no effect on BaF3 cells transduced with 
CRLF2–IL-7R WT. Similarly, cells transduced with IL-7R 
InsPPCL also responded to TSLP, in addition to marked self-
activation of this allele (Fig. S3).
Loss-of-function mutations in IL-7R cause severe com-
bined immunodeficiency characterized by the complete ab-
sence of T lymphocytes and the presence of B and NK cells 
(Puel et al., 1998). Both B- and T-ALLs express IL-7R and 
have been reported to respond to IL-7 (Touw et al., 1990). 
We have therefore hypothesized that gain-of-function mu-
tations in IL-7R may also be detected in T-ALL. Accord-
ingly, we screened 295 diagnostic childhood T-ALL samples 
treated on prospective BFM protocols (Kox et al., 2010) for 
IL7R mutations and identified 30 somatic mutations (10.5%). 
All the mutations were at the transmembrane domain encoded 
Figure 1.  Somatic mutations of IL7R (NM_002185.2) in patients 
with BCP-ALL. (A) IL7R mutation localization. Amino acid numbers of 
the different domains are indicated. (B) Sequences of IL7R insertions and 
deletions mutations at the transmembrane domain. The inserted se-
quences are within brackets (All Ins-Del mutations were heterozygous, 
only the mutated allele is shown after allele separation). N, sites with both 
WT and mutant allele at the same position; Ins, insertion; Del, deletion.  
(C) Alignment of WT and mutated IL7R transmembrane domain se-
quences. Numbers show the positions of nucleotides and corresponding 
amino acids. The inserted amino acids are shown in red, with the cysteine 
residue in bold. (D) Expression of mutations: Examples of two mutated  
IL-7R sequences with S185C and c.814 Ins 13 Del A. The mutated allele is 
expressed in the RNA from diagnosis, but not in remission samples.
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by exon 6, and all but one were in-frame insertions and de-
letions (Table II); 27 of the 30 cases included an insertion of 
cysteine.  The  patients  with  mutations  were  younger  and 
tended to have higher white blood cells counts at diagnosis 
(Table S1). There was no association between the presence 
of the mutations and response to therapy, and a similar pro-
portion (10%) relapsed. Notch mutations, which hallmark 
50% of T-ALLs (Clappier et al., 2010; Kox et al., 2010), 
were detected in 64% of the IL7R-mutated leukemias com-
pared with 48% of the T-ALL without IL7R mutations (P = 
0.1, 2 test).
We and others (Hertzberg et al., 2010; Yoda et al., 2010) 
have  recently  reported  an  activating  F232C  mutation  in 
CRLF2 that introduces cysteine in the juxtamembrane do-
main. All but three of the mutations observed in IL-7R 
included the addition of cysteine. To study whether the gain-
of-function of the mutated IL-7R could be attributed to the 
addition of cysteine, we replaced the cysteines in the S815C 
and in the IL-7R InsPPCL alleles with glycine. These newly 
mutated receptors were expressed at the cell surface of trans-
duced BaF3 cells (Fig. 4 A). Elimination of the cysteine abro-
gated the cytokine-independent growth (Fig. 4 B) and the 
constitutive phosphorylation of Stat5 (Fig. 4 C). Response to 
TSLP was not altered, confirming that “cysteine-lacking” 
mutated  IL-7R  formed  a  functional  TSLP  receptor  with 
CRLF2 (Fig. 4 C). These results suggest that the presence of 
cysteine is critical for the gain-of-function phenotype both in 
the context of insertion of additional amino acids and as a 
point mutation.
The experimental insertion of cysteine into the transmem-
brane domain of the erythropoietin receptor (Constantinescu 
et al., 2001; Lu et al., 2006) activated the receptor by causing 
ligand-independent receptor dimerization. Indeed, we ob-
served marked homodimerization of the IL-7R InsPPCL in 
protein analysis under nonreducing conditions (Fig. 4 D). In-
terestingly, CRLF2 was not present in these dimers, which is 
consistent with the observation that this mutant protein does 
not require CRLF2 for its activation and with the presence of 
these mutations in T-ALLs in which CRLF2 is not highly 
expressed. Our current and recent observations (Chapiro 
et al., 2010; Hertzberg et al., 2010; Yoda et al., 2010) of 
mutations in IL-7R and CRLF2, respectively, suggest that 
the addition of cysteine to the juxtamembranous domain is a 
general mechanism for mutational activation of type I cyto-
kine receptors in leukemias.
These discoveries are a prime example of the intercon-
nection of development and leukemia (Izraeli, 2004). Al-
though loss-of-function mutations in IL-7R perturb lymphoid 
development, the novel gain-of-function mutations described 
here are associated with both BCP- and T-ALLs. Activating 
mutations of IL-7R are present in leukemias of the same 
lineage, for which it is developmentally required (T cells), or in 
B cell precursor leukemias that aberrantly express a T cell and 
monocytic receptor (CRLF2). The broad significance of this 
pathway in leukemia is further suggested by the aberrant 
deregulation of CRLF2–JAK–STAT pathway in BCP-ALL 
Figure 2.  IL7R mutations are gain-of-function mutations.  
(A) FACS analysis of BaF3 cells stably transduced with CRLF2 and either 
IL-7R WT, IL-7R S185C, or IL-7R InsPPCL in the presence of IL-3. The 
same cells were then grown without IL-3 for 1 wk and then analyzed 
again. (B) Cytokine withdrawal assay of BaF3 and BaF3-CRLF2 cells 
transduced with either IL-7R WT, IL-7R S185C, or IL-7R InsPPCL. Error 
bars represent SE. (C) Constitutive phosphorylation of Stat5 and ribo-
somal protein S6 (RPS6) in BaF3 and BaF3-CRLF2 cells expressing IL-7R 
mutants, after 5 h of cytokine deprivation. IL-3+ indicates cells har-
vested after 5 h of IL-3 deprivation followed by 20 min of IL-3 stimula-
tion. All experiments were repeated four times.JEM VOL. 208, May 9, 2011  905
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activating mutations in T-ALL (Flex et al., 2008; Hornakova 
et al., 2010). Similar to mutational activations of other growth 
factor receptors in cancer (Gazdar, 2009), our observations 
have potential implications for targeted therapy.
(Bercovich et al., 2008; Constantinescu et al., 2008; Kearney 
et al., 2009; Mullighan et al., 2009; Russell et al., 2009; 
Hertzberg et al., 2010; Yoda et al., 2010) and by these newly 
described IL7R mutations and the previously reported JAK1 
Figure 3.  CRLF2 and mutated IL7R form a functional TSLP receptor and sensitize cells to TSLP. (A) BaF3 cells expressing CRLF2 and either WT  
or mutated IL-7R were starved of IL-3 for 5 h, and then treated or not with 100 ng/ml TSLP where indicated for 25 min. (B) BaF3-CRLF2 cells transduced 
with either WT IL-7R or IL-7R S185C were treated with increasing doses of TSLP in the absence of IL-3. The number of cells was normalized to day 0 
(therefore relative growth was measured). Experiments were performed three times. Error bars indicate SE.
Table II.  IL7R mutations in T-ALL
ID IL7R mutation DNA IL-7R mutation protein
T1 c.816 Ins 15 TTTTGTCGGAAGGAC 243 Ins FCRKD
T2 c.815 Ins 7 GAGATGC Del 1 A 243 Ins RC
T3 c.818Ins 10 CGTGCCCCCT Del 4 TAAC 243 Ins PCPL
T4 c.820 Ins 21 TGCCCGAGCAAGATTGCCCCA + point mutation c826 G->C 244 Ins MPEQDCP +S246T
T5 c.798 Ins 11 CCTCCTGGTGC Del 17 AGATGGATCCTATCTTA 237 Ins ASWC
T6 c.814 Ins 6 GCCCCC Del 6 TACTAA 242 Ins CPP
T7 c.817 Ins 11 GCTGCCCGTCC Del 2 TA 243 Ins RCPS
T8 c.815 Ins 16 CGACTGTATTGGGGGTC Del 1 A 242 Ins FDCIGV
T9 c.822 Ins 10 CACCGTGGGT Del 4 ATCA 245 Ins HRGC
T10 c.817 Ins 12 CCCTCTGTTCGG Del 3 TAA 243 Ins PLCSA
T11 c.849 Ins 9 GAGAGGCCG 254 Ins GEA
T12 c.817 Ins 19 CCATTTATCGGTGTGTCCT Del 4 TAAC 243 Ins PIYRCVL
T13 c.799 Ins 11 CCTCCTGGTGC Del 17 AGATGGATCCTATCTTA 237 Ins ASWC
T14 c.816 Ins 7 TGAGTGT Del 1 A 242 Ins FEC
T15 c.815 Ins 11 TACCTGCCCGT Del 5 ACTAA 242 Ins FTCPS
T16 c.816 Ins 11 TGCCCCTCTCC Del 2 CT 243 Ins CPSP
T17 c.850 Ins 6 AAAAAG Del 3 CTC 254 Ins EKV
T18 c.823 Ins 12 GTCATCAGCCCT Del 3 TCA 245 Ins SHQPC
T19 c.838 Ins 24 GTTCAACCATCAGCATTTTGAGTT 250 Ins CSTISILS
T20 c.832 Ins 7 GTCAAAG Del 13 TGAGTTTTTTCTC 248 Ins CQ
T21 c. 814 Ins 14 GTGGTATAAGGGAA Del 5 TACTA 242 Ins CGIREI
T22 c. 847 T>G V253G
T23 c. 817 Ins 6 GGCTGT 243 Ins RC
T24 c.817 Ins 6 GCTGTA 244 Ins GC
T25 c.809 Ins 13 GTGCCGTCCCCAT Del 7 TATCTTA 241 Ins CRPH
T26 c.816 Ins 7 GGCTGTA Del 1 C 243 Ins GCI
T27 c.821 Ins 12 GAGGCCTTGTGG 245 Ins RPCG
T28 c.821 Ins 15 ACTTCCCTGCGTCTAC 245 Ins LPCVT
T29 c.814 Ins 10 GCTGGATGAA Del 1 T 242 Ins CWMK
T30 c.820 Ins 13 AGAAATGCACAAA Del 1 C 244 Ins KKCTN
Del, Deletion; Ins, Insertion. The amino acid cysteine included in 27 of 30 mutations is shown in bold.906 IL7R mutations in acute lymphoblastic leukemia | Shochat et al.
30 s, 58°C for 30 s, and 
72°C 30 s, followed by 
30  cycles  of  94°C  for 
30 s, 55°C for 30 s, and 
72°C 30 s, followed by 1 cycle of 72°C for 7 min. We then analyzed the 
fragments by denaturing high-performance liquid chromatography as de-
scribed before (Bercovich et al., 2008; Hertzberg et al., 2010).
Fragments with abnormal chromatography patterns were sequenced di-
rectly by the primer used for PCR, or cloned into TA vector pCR2.1 
(Invitrogen). DNA from plasmid clones was extracted by AccuPrep Spin 
Miniprep kit (Bioneer) and sequenced.
Site-directed mutagenesis. The human IL7R cloned into the MSCVires-
GFP retrovirus (encoding GFP) was used as a template for the generation of 
mutations by site-directed mutagenesis (QuikChange II XL; Stratagene). 
The plasmid sequences were verified by sequencing.
BaF3 assays. Parental BaF3 cells and those expressing human CRLF2 re-
ceptor (BaF3/CRLF2; Hertzberg et al., 2010) were transduced with the 
retroviruses containing WT or mutant IL7R. Transduced cells were sorted 
by flow cytometer 2–4 d later. PE anti–human CRLF2 (322806; BioLegend) 
and Alexa Fluor 647 anti–human CD127 (IL-7R, 317606; BioLegend) anti-
bodies were used. Cytokine withdrawal assays were performed as previously 
described (Hertzberg et al., 2010)
Western blotting. For Western blot analyses, 10% polyacrylamide linear 
gels were used. BaF3 cells were harvested after 5 h of IL-3 deprivation, and 
then stimulated with either 10 ng/ml IL-3 or 100 ng/ml TSLP for 25 min. 
The antibodies used were anti–phospho-STAT5 Tyr 694 (Epitomics), anti-
STAT5, anti-S6 ribosomal protein and anti-phospho-S6 ribosomal protein 
Ser 235/6 (Cell Signaling Technology).
For Western blot analyses of disulfide-bonded dimmers, 8% polyacryl-
amide linear gels were used. For nonreducing conditions, proteins were 
boiled in SDS buffer without 2-mercaptoethanol. Antibodies used were 
anti–human IL-7R (R&D Systems) and anti–human CRLF2 (BioLegend).
Online  supplemental  material.  Fig.  S1  shows  expression  of  mutated 
IL7R. Fig. S2 shows FACS analysis of parental BaF3 cells in the presence 
of IL-3. Fig. S3 shows CRLF2 and IL7R Ins PPCL respond to TSLP. 
Table S1 shows the clinical characteristics of T-ALL patients with IL7R 
MATERIALS AND METHODS
Patient samples. DNA and RNA were derived from leukemic bone mar-
row of children with ALL enrolled in a prospective BFM (Berlin Frankfurt 
Munster) and AIEOP (Associazione Italiana Ematologia Oncologia Pediat-
rica Group) ALL 2000 study (Conter et al., 2010). The T-ALL and the DS-
ALL cohorts were previously described (Hertzberg et al., 2010; Kox et al., 
2010). All specimens were collected with informed consent and approval of 
local and national ethic committees. Samples were anonymized for the study. 
The study was approved by the Israeli Health Ministry Ethic committee, ap-
proval # 920070771.
CRLF2 analysis. CRLF2 levels were analyzed by the TaqMan Gene Ex-
pression Assay Hs00913509_s1 (Applied Biosystems), as we have previously 
reported (Cario et al., 2010; Hertzberg et al., 2010). The presence of the fu-
sion transcript P2RY8-CRLF2 was analyzed by RT-PCR, as we have previ-
ously reported (Cario et al., 2010; Hertzberg et al., 2010), using primers 
designed  in  the  first  exon  of  P2RY8  (5-GGACAGATGGAACTG-
GAAGG-3) and the third exon of CRLF2 (5-GTCCCATTCCTGATG-
GAGAA-3). PCR product was 511 bp. Immunoglobulin heavy chain 
locus (IGH) translocations were identified by fluorescence in situ hybrid-
ization (FISH) on interphase nuclei using the Vysis LSI IGH Dual Color 
Break-Apart Rearrangement Probe (Abbott Molecular). The nuclei were 
counterstained with DAPI (4, 6-diamino-2-phenylindol). Results were re-
corded  using  a  fluorescence  microscope  (DMRB;  Leica)  fitted  with  a 
100×/1.30 oil objective, charge-coupled device camera, and digital imaging 
software from MetaSystems (Isis FISH imaging system).
For the purpose of this study, the CRLF2-positive group consisted of 
BCP-ALL specimens that were either positive for the P2RY8-CRLF2 fu-
sion or to the IGH CRLF2 translocation or had CRLF2 RNA expression 
levels >20 fold of the median value of CRLF2 expression of 555 un-
selected BCP-ALLs (Cario et al., 2010). The CRLF2-negative group con-
sisted of BCP-ALL specimens negative for the genomic rearrangements 
and with expression level at the median and below. JAK2 and CRLF2 
mutations were identified as previously described (Hertzberg et al., 2010)
IL7R mutation analysis. We used intronic primers of human IL7R se-
quence  (available  from  GenBank/EMBL/DDBJ  under  accession  no. 
NM_002185.2; Table S2) to amplify exons 1–8 of the gene with PCR. Fast 
start Taq DNA polymerase (Roche) was used with the following thermal cy-
cling conditions: 1 cycle of 94°C for 5 min, followed by 5 cycles of 94°C for 
Figure 4.  Functional significance of the 
cysteine residue in mutated IL7R. (A) FACS 
analysis of BaF3-CRLF2 cells expressing either 
S185G or IL-7R InsPPGL. In these constructs, 
the cysteine was mutated to glycine.  
(B) Growth assay of BaF3 and BaF3-CRLF2 
cells transduced with IL-7R WT, IL-7R S185G, 
or IL-7R InsPPGL in the presence or absence 
of 30 ng/ml TSLP and the absence of IL-3. 
Error bars indicate SE. (C) BaF3 and BaF3-
CRLF2 cells expressing indicated IL-7R mu-
tants were incubated without IL-3 for 5 h. 
Where indicated, 100 ng/ml TSLP was added 
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